LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! The week has been very quiet, but that was to be expected since a major genitourinary oncology conference is coming up in about ten days. Still, I’m expecting news very soon! Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.

Clinical Research

• Phase 2b Trial of Teverelix in Advanced Prostate Cancer Patients at High Cardiovascular Risk
  ​The FDA has cleared a Phase 2b clinical trial for teverelix, a long-acting GnRH antagonist designed for men with advanced prostate cancer who are at high cardiovascular risk. This study will enroll approximately 40 patients to test a 22-week dose-optimization regimen, with the primary goal of sustaining testosterone suppression through day 155 at a probability exceeding 90%. Teverelix is a microcrystalline suspension administered intramuscularly and subcutaneously that provides immediate blockade of gonadotropin release without the testosterone surge typically seen with traditional GnRH agonists. The trial addresses a critical clinical need, as cardiovascular disease accounts for roughly 30% of deaths in men with prostate cancer.

Preclinical Research & Reviews

• Molecular Fingerprints and Spatial Multi-Omics in Aggressive Prostate Cancer
  ​Researchers have utilized spatial multi-omics to analyze prostate tissue from patients, creating a three-dimensional molecular map that integrates transcriptomics, metabolomics, and digital histopathology. By comparing samples from patients who relapsed with those who remained cancer-free, the study identified a distinct gene expression pattern that marks aggressive prostate cancer and could eventually serve as a test to guide treatment intensity. A key discovery was that seemingly normal tissue adjacent to tumors exhibited significant inflammation and metabolic disruption, indicating that the cancer’s influence extends into the surrounding microenvironment. The ultimate vision for this research is to develop simpler assays, such as blood or semen tests, that can identify aggressive biology without requiring invasive biopsies.
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max